| Schedule of components of income tax expense (benefit) |
| Schedule of components of income tax expense (benefit) |
|
|
|
|
|
|
| |
|
2023 |
|
|
2022 |
|
| |
|
|
|
|
|
|
| Expected federal income tax benefit at statutory rate |
|
$ |
9,464,954 |
|
|
$ |
7,184,840 |
|
| Non-deductible expenses |
|
|
1,183,767 |
|
|
|
(288,249 |
) |
| Research and development credit |
|
|
– |
|
|
|
595,244 |
|
| Return to provision true up |
|
|
108,959 |
|
|
|
93,285 |
|
| Change in valuation allowance |
|
|
(10,757,680 |
) |
|
|
(7,585,120 |
) |
| Income tax benefit |
|
$ |
– |
|
|
$ |
– |
|
|
| Schedule of deferred tax assets and liabilities |
| Schedule of deferred
tax assets and liabilities |
|
|
|
|
|
|
| |
|
2023 |
|
|
2022 |
|
| Deferred tax assets |
|
|
|
|
|
|
|
|
| Net operating losses |
|
$ |
15,468,757 |
|
|
$ |
9,106,430 |
|
| Debt basis difference |
|
|
5,121,397 |
|
|
|
– |
|
| Depreciation and amortization |
|
|
1,701,768 |
|
|
|
1,502,868 |
|
| Research & development credit |
|
|
1,099,535 |
|
|
|
1,308,956 |
|
| Lease liability |
|
|
246,704 |
|
|
|
322,167 |
|
| Stock-based compensation |
|
|
3,235,732 |
|
|
|
3,103,037 |
|
| Inventory |
|
|
152,749 |
|
|
|
1,290,968 |
|
| Accrued expenses |
|
|
66,909 |
|
|
|
233,284 |
|
| Capital loss carryover |
|
|
176,950 |
|
|
|
261,922 |
|
| Dealer rebates |
|
|
459,713 |
|
|
|
161,469 |
|
| Other |
|
|
21,828 |
|
|
|
15,605 |
|
| Total |
|
|
27,752,042 |
|
|
|
17,306,705 |
|
| Valuation allowance |
|
|
(27,171,016 |
) |
|
|
(16,661,612 |
) |
| Net deferred tax asset |
|
|
581,026 |
|
|
|
645,093 |
|
| Deferred tax liabilities |
|
|
|
|
|
|
|
|
| Prepaid expenses |
|
|
(342,421 |
) |
|
|
(328,836 |
) |
| Right-of-use assets |
|
|
(238,605 |
) |
|
|
(316,257 |
) |
| Total net deferred taxes Deferred tax liabilities |
|
$ |
– |
|
|
$ |
– |
|
|